{"id":"W2556217933","doi":"10.1182/blood.v112.11.lba-1.lba-1","title":"Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Fludarabine; Medicine; Rituximab; Internal medicine; Tolerability; Clinical endpoint; Regimen; Progression-free survival; Gastroenterology; Refractory (planetary science); Cyclophosphamide; Surgery; Randomized controlled trial; Oncology; Chemotherapy; Adverse effect; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002508804,0.000529477,0.001652797,0.0002101684,0.0002709224,0.00007820255,0.0007485409,0.00032147,0.0001142535],"category_scores_gemma":[0.003558289,0.0003093191,0.0001907198,0.0005128966,0.001075122,0.0001958201,0.000354122,0.0008730479,0.00003255414],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01701982,"about_ca_system_score_gemma":0.0309637,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007944983,"about_ca_topic_score_gemma":0.002193616,"domain_scores_codex":[0.994233,0.0006553192,0.001374008,0.001073624,0.001891151,0.0007729639],"domain_scores_gemma":[0.9948222,0.002825987,0.0005056559,0.001261161,0.0002653242,0.0003196475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9879777,0.002065838,0.000144343,0.00006683502,0.0005858833,0.003437198,0.001337626,0.00005405323,0.0006535739,0.000008788841,0.002143554,0.001524577],"study_design_scores_gemma":[0.9681836,0.002762928,0.000585379,0.0008457784,0.0004300395,0.001019215,0.000116999,0.02299431,0.001607232,0.00003673479,0.001052071,0.0003657537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9907342,0.002468362,0.00001913351,0.0006353688,0.0003817818,0.004601077,0.000191032,0.0001527094,0.0008163959],"genre_scores_gemma":[0.9943024,0.001067051,0.0009779024,0.0001296591,0.00101696,0.0005983792,0.0007877674,0.00008384563,0.001036021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02294026,"threshold_uncertainty_score":0.9999359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03445272499857231,"score_gpt":0.3069382083251383,"score_spread":0.272485483326566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}